News Archive

A new five-year collaboration between Johns Hopkins University and biopharmaceutical company Bristol-Myers Squibb aims to determine why some patients being treated for cancer respond to immunotherapy drugs called checkpoint blockers and some do not, and to develop more effective combination immunotherapies.

Projects included in the collaboration will span laboratory research on patients’ tumor samples and several early-stage clinical trials led by Johns Hopkins scientists at the Bloomberg-Kimmel Institute for Cancer Immunotherapy.

Thu, November 17, 20164:30 PM – 8:30 PM EST

Join more than 400 of the region’s business and government leaders for the Economic Alliance of Greater Baltimore’s Annual Meeting, November 17, 2016 at the Baltimore Marriott Waterfront. While Maryland is known for its history and culture, food and beautiful landscape, this year’s annual meeting will celebrate one of the region’s greatest assets – the people – as they tell their stories.  The program will recognize the region’s growing companies and those who make our community a world-class market in which to live, work, learn and invest.

miDIAGNOSTICS, global developer of integrated diagnostic solutions for the point-of-need, announces that it has established a collaboration with emocha Mobile Health Inc. from Baltimore, MD, USA. A Johns Hopkins startup company, emocha has developed a platform of digital mobile applications that streamline the continuum of care. The goal of the collaboration is to enable mobile health solutions based on the miniaturized products for point-of-need under development by miDIAGNOSTICS.

Qiagen N.V., a leading global provider of sample to insight solutions, announced the validation of new and improved sequencing  chemistry for its GeneReader NGS System, the world’s first complete Sample to Insight solution making the benefits of next-generation sequencing (NGS) accessible to any laboratory.

Qiagen published new, excellent performance data of the Qiagen GeneReader NGS System using the new sequencing chemistry and Qiagen’s GeneRead QIAact Actionable Insights Tumor Panel. Data generated from the GeneReader NGS System with the new chemistry showed 100% concordance with results of Qiagen’s FDA approved therascreen KRAS RGQ PCR assay, the company’s CE-labelled therascreen RAS Extension Pyro Assay as well as with an alternative next-generation sequencing (NGS) sequencer from another vendor. In this study, 42 metastatic colorectal cancer FFPE samples were tested with previously confirmed RAS mutational status.

NOVEMBER 16, 2016 5:00pm to 6:30pm

Host:  UM BioPark & Wexford Science + Technology

Location:  UM BioPark Invent & Advance Conference Rooms 801 W. Baltimore Street Baltimore  Maryland  21201

Please join the BioPark’s Monthly Networking Event. Mingle with UM Venture program managers, BioPark tenants, and UMB faculty and staff.

An end to Obamacare and a less aggressive approach to drug pricing expected

Pharmaceutical stocks surged in Europe on Wednesday as Republican Donald Trump’s U.S. presidential election win led investors to conclude the threat of tough action on drug pricing had receded.

Nominations are open for the 2017 Industry Awards Celebration. This will be our 29th year of recognizing the companies and individuals in the region who make a difference.

The Tech Council ignites the power of three by bringing together a trio of industries that are accelerating our local ecosystem—technology, life sciences, and health IT. It’s our mission to make this region a top three innovation economy, so we’re redefining what’s possible and helping to shape the future through ideation, collaboration, and innovation.

Concerns over the role of the Center for Medicare & Medicaid Innovation could lead to legislation intended to hinder the agency and slow its attempts to further the goal of paying providers for value rather than volume.

While no specific legislative language has surfaced, multiple sources confirmed that Republicans upset with what they say is overreach by the CMS Innovation Center, also known as CMMI, are considering a legislative response. A few Republicans have previously said they would support repealing the agency entirely or zeroing out its budget. More modest efforts could include banning mandatory participation in payment models.

Get in the habit of producing good financial reports every single month. But you need more than just standard financial reports. You need a Management Dashboard that monitors critical metrics that may not pop out of your accounting reports. These monthly reports are a learning opportunity: What did we think would happen? What actually happened? Why was there a difference? Are we on track to hit our key milestones?

Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, today announced they are now accepting applications for their Cancer Discovery Incubator Award.

After experiencing partnering success and a $315 million deal with Japan-based Astellas Pharma Inc. for their LAMP-Vax platform technology in allergy, Immunomic Therapeutics, in concert with BioHealth Innovation, is giving back to the region’s growing scientific community with the Cancer Discovery Incubator Award. The incubator will enable and accelerate beginning ventures aimed at offering measurable change in oncological healt